Soy isoflavones avert chronic inflammation-induced bone loss and vascular disease

被引：39

作者：

Droke E.A. ^{[1
]}

Hager K.A. ^{[2
]}

Lerner M.R. ^{[3
,4
]}

Lightfoot S.A. ^{[4
,5
]}

Stoecker B.J. ^{[2
]}

Brackett D.J. ^{[3
,4
]}

Smith B.J. ^{[2
,6
]}

机构：

[1] Department of Nutrition, Food Science and Hospitality, South Dakota State University, Brookings

[2] Department of Nutritional Sciences, Oklahoma State University, Stillwater

[3] Department of Surgery, University of Oklahoma, Health Sciences Center, Oklahoma City

[4] Veterans Affairs Medical Center, Oklahoma City

[5] Department of Pathology, University of Oklahoma, Health Sciences Center, Oklahoma City

[6] Department of Medicine, University of Oklahoma, Health Sciences Center, Oklahoma City

来源：

Journal of Inflammation | / 4卷 / 1期

关键词：

Trabecular Bone; Structure Model Index; Distal Femur Metaphysis; Trabecular Bone Microarchitecture; Bone Biomechanical Property;

D O I：

10.1186/1476-9255-4-17

中图分类号：

学科分类号：

摘要：

Background. Evidence from epidemiological, clinical and animal studies suggests a link may exist between low bone density and cardiovascular disease, with inflammatory mediators implicated in the pathophysiology of both conditions. This project examined whether supplementation with soy isoflavones (IF), shown to have anti-inflammatory properties, could prevent tissue expression of TNF-α and the development of skeletal pathology in an animal model of chronic inflammation. Methods. Eight-week old, intact, female C57BL/6J mice were used. In Phase 1, a lipopolysaccharide (LPS)-dose response study (0, 0.133, 1.33 and 13.3 μg/d) was conducted to determine the LPS dose to use in Phase 2. The results indicated the 1.33 μg LPS/d dose produced the greatest decrease in lymphocytes and increase in neutrophils. Subsequently, in Phase 2, mice were randomly assigned to one of six groups (n = 12-13 per group): 0 or 1.33 μg LPS/d (placebo or LPS) in combination with 0, 126 or 504 mg aglycone equivalents of soy IF/kg diet (Control, Low or High dose IF). Mice were fed IF beginning 2 wks prior to the 30-d LPS study period. Results. At the end of the study, no differences were detected in final body weights or uterine weights. In terms of trabecular bone microarchitecture, μCT analyses of the distal femur metaphysis indicated that LPS significantly decreased trabecular bone volume (BV/TV) and number (TbN), and increased separation (TbSp). Trabecular bone strength (i.e. total force) and stiffness were also compromised in response to LPS. The High IF dose provided protection against these detrimental effects on microarchitecture, but not biomechanical properties. No alterations in trabecular thickness (TbTh), or cortical bone parameters were observed in response to the LPS or IF. Immunohistomchemical staining showed that tumor necrosis factor (TNF)-α was up-regulated by LPS in the endothelium of small myocardial arteries and arterioles as well as the tibial metaphysis and down-regulated by IF. Conclusion. These results suggest IF may attenuate the negative effects of chronic inflammation on bone and cardiovascular health. Additional research is warranted to examine the anti-inflammatory properties of the soy isoflavones and the mechanisms underlying their prevention of chronic inflammation-induced bone loss. © 2007 Droke et al; licensee BioMed Central Ltd.

引用

共 52 条

[1]

Von Der Recke P., Hansen M.A., Hassager C., The association between low bone mass at the menopause and cardiovascular mortality, Am J Med, 106, pp. 273-278, (1999)

[2]

Kado D.M., Browner W.S., Blackwell T., Gore R., Cummings S.R., Rate of bone loss is associated with mortality in older women: A prospective study, J Bone Miner Res, 15, pp. 1974-1980, (2000)

[3]

Hak A.E., Pols H.A., Van Hemert A.M., Hofman A., Witteman J.C., Progression of aortic calcification is associated with metacarpal bone loss during menopause: A population-based longitudinal study, Arterioscler Thromb Vasc Biol, 20, pp. 1926-1931, (2000)

[4]

Kiel D.P., Kauppila L.I., Cupples L.A., Hannan M.T., O'Donnell C.J., Wilson P.W., Bone loss and the progression of abdominal aortic calcification over a 25 year period: The Framingham Heart Study, Calcif Tissue Int, 68, pp. 271-276, (2001)

[5]

Van Der Klift M., Pols H.A., Hak A.E., Witteman J.C., Hofman A., De Laet C.E., Bone mineral density and the risk of peripheral arterial disease: The Rotterdam Study, Calcif Tissue Int, 70, pp. 443-449, (2002)

[6]

Kenny A.M., Boxer R., Walsh S., Hager W.D., Raisz L.G., Femoral bone mineral density in patients with heart failure, Osteoporos Int, 17, pp. 1420-1427, (2006)

[7]

Tanko L.B., Christiansen C., Cox D.A., Geiger M.J., McNabb M.A., Cummings S.R., Relationship between osteoporosis and cardiovascular disease in postmenopausal women, J Bone Miner Res, 20, pp. 1912-1920, (2005)

[8]

Romas E., Gillespie M.T., Martin T.J., Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis, Bone, 30, pp. 340-346, (2002)

[9]

Mikuls T.R., Co-morbidity in rheumatoid arthritis, Best Pract Res Clin Rheumatol, 17, pp. 729-752, (2003)

[10]

Lessem J., Periodontitis in cardiology - A clinical perspective, J Int Acad Periodontol, 7, pp. 49-54, (2005)

← 1 2 3 4 5 6 →